Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $44.33 USD
Change Today -1.63 / -3.55%
Volume 385.5K
As of 8:04 PM 09/3/15 All times are local (Market data is delayed by at least 15 minutes).

cambrex corp (CBM) Snapshot

Open
$46.30
Previous Close
$45.96
Day High
$46.76
Day Low
$44.19
52 Week High
08/5/15 - $54.60
52 Week Low
10/15/14 - $15.76
Market Cap
1.4B
Average Volume 10 Days
559.9K
EPS TTM
$1.11
Shares Outstanding
31.4M
EX-Date
05/4/07
P/E TM
39.9x
Dividend
--
Dividend Yield
--
Current Stock Chart for CAMBREX CORP (CBM)

cambrex corp (CBM) Related Bloomberg News

View More Bloomberg News

cambrex corp (CBM) Related Businessweek News

No Related Businessweek News Found

cambrex corp (CBM) Details

Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. The company’s products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products. It serves generic drug companies, and companies that discover and commercialize small molecule human therapeutics. The company sells its products directly, as well as through independent agents. Cambrex Corporation was founded in 1981 and is headquartered in East Rutherford, New Jersey.

1,117 Employees
Last Reported Date: 02/6/15
Founded in 1981

cambrex corp (CBM) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $550.0K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $427.5K
Chief Operating Officer and Executive Vice Pr...
Total Annual Compensation: $450.3K
Managing Director of Cambrex Profarmaco Milan...
Total Annual Compensation: $357.1K
Compensation as of Fiscal Year 2014.

cambrex corp (CBM) Key Developments

Cambrex Corporation. Announces the Resignation of Aldo Magnini as Executive Officer

Effective August 19, 2015, Aldo Magnini, one of named executive officers, will no longer be designated as an executive officer of Cambrex Corporation. Mr. Magnini continues to serve in his role as Managing Director, Cambrex Profarmaco Milano Srl.

Cambrex Corporation Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Revises Earnings Guidance for the Full Year of 2015

Cambrex Corporation announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported net sales of $106,014,000 against $97,347,000 a year ago. Net revenues were $106,635,000 against $97,893,000 a year ago. Operating profit was $29,164,000 against $15,224,000 a year ago. Income before income taxes was $28,922,000 against $10,412,000 a year ago. Income from continuing operations was $19,450,000 or $0.60 diluted per share against $19,827,000 or $0.63 diluted per share a year ago. Net income was $19,663,000 or $0.61 diluted per share against $19,667,000 or $0.63 diluted per share a year ago. EBITDA was $34,552,000 against $21,190,000 a year ago. Adjusted income from continuing operations was $20,478,000 $0.63 diluted per share against $10,963,000 or $0.35 diluted per share a year ago. The sales increase primarily reflects higher volumes of certain branded active pharmaceutical ingredients (APIs) and to a lesser extent, higher pricing on certain products. The increase in operating profit was primarily the result of higher gross profit and lower operating expenses. Capital expenditures were $14.5 million compared to $6.0 million a year ago. For the six months, the company reported net sales of $183,747,000 against $162,990,000 a year ago. Net revenues were $184,160,000 against $163,998,000 a year ago. Operating profit was $41,837,000 against $17,694,000 a year ago. Income before income taxes was $41,057,000 against $12,032,000 a year ago. Income from continuing operations was $27,818,000 or $0.86 diluted per share against $20,993,000 or $0.67 diluted per share a year ago. Net income was $27,656,000 or $0.86 diluted per share against $20,649,000 or $0.66 diluted per share a year ago. EBITDA was $52,522,000 against $29,543,000 a year ago. Adjusted income from continuing operations was $29,715,000 $0.92 diluted per share against $12,925,000 or $0.41 diluted per share a year ago. Capital expenditures for the first half of 2015 were $26.4 million. The company revised earnings guidance for the full year of 2015. For the year, the company expects gross sales increase in the range of between 20% - 24%, adjusted EBITDA in the range of between $117 million - $123 million, adjusted income from continuing operations per share in the range of between $1.97 - $2.09, capital expenditures in the range of between $80 million - $85 million and effective tax rate in the range of between 33% - 36% against previous guidance of gross sales increase in the range of between 16% - 20%, adjusted EBITDA in the range of between $101 million - $107 million, adjusted income from continuing operations per share in the range of between $1.62 - $1.75, capital expenditures in the range of between $80 million - $85 million and effective tax rate in the range of between 33% - 36%.

Cambrex Corporation. to Report Q2, 2015 Results on Jul 30, 2015

Cambrex Corporation. announced that they will report Q2, 2015 results Pre-Market on Jul 30, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CBM:US $44.33 USD -1.63

CBM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Aceto Corp $22.15 USD +0.40
Albany Molecular Research Inc $19.99 USD -0.02
Biocon Ltd 427.50 INR -12.20
Produits Chimiques Auxiliaires et de Synthese €4.54 EUR +0.05
Siegfried Holding AG SFr.175.50 CHF +2.50
View Industry Companies
 

Industry Analysis

CBM

Industry Average

Valuation CBM Industry Range
Price/Earnings 22.7x
Price/Sales 3.6x
Price/Book 5.3x
Price/Cash Flow 22.4x
TEV/Sales 3.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CAMBREX CORP, please visit www.cambrex.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.